AngioDynamics (NASDAQ: ANGO) reported fiscal Q2 2026 results: net sales $79.4M
(+8.8% pro forma) and Med Tech sales $35.7M (+13.0%). GAAP net loss was $6.4M (loss per share $0.15) and adjusted loss per share was $0.00. Adjusted EBITDA was $5.9M and cash was $41.6M.
The company secured three regulatory milestones for its Mechanical Thrombectomy portfolio (APEX-Return IDE, PAVE IDE, modified AlphaVac 510(k)), concluded patent litigation with Bard, and raised FY2026 net sales guidance to $312–$314M and adjusted EBITDA to $8–$10M. CEO Jim Clemmer will retire upon successor appointment expected in fiscal 2027.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.